Search
Disc Medicine Inc
IRONAdd to Watchlist
74.950USD
+1.810+2.47%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
2.84BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
13
analysts
Buy
Current Rating
101.000
Target Price
+38.09%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Disc Medicine Inc
IRON
13
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Disc Medicine Inc's price target?
Analysts forecast that Disc Medicine Inc's price target is USD 110.00, with the highest forecast at USD 153.00 and the lowest forecast at USD 85.00.
How have Disc Medicine IncIRON's recent earnings per share performed?
The market expectation was USD -1.65, while Disc Medicine IncIRON's earnings per share (EPS) for the previous quarter was USD -1.61. EPS for the next quarter is expected at USD -1.77.
What is the analyst rating for Disc Medicine Inc?
Based on the ratings of Disc Medicine Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.